Tumor Biology

, Volume 35, Issue 10, pp 10185–10193 | Cite as

Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction

  • Zhengfa Mao
  • Xiaoyan Ma
  • Xin Fan
  • Lei Cui
  • Ting Zhu
  • Jianguo Qu
  • Jianxin Zhang
  • Xuqing WangEmail author
Research Article


Aberrant secreted protein acidic and rich in cysteine (SPARC) expression has been reported to play an important role in the tumor development. However, the pattern and the role of SPARC in pancreatic cancer remain largely unknown. Therefore, we further deciphered the role of SPARC played in pancreatic cancer. We first evaluated the SPARC expression in human pancreatic cancer tissues and pancreatic cancer cells. Then we forced expression and silenced SPARC expression in pancreatic cancer cell lines MIA PaCa2 and PANC-1, respectively, using lentivirus vectors. We characterized the stable cells in vitro. In this study, we found that SPARC expression was weak in cancer cells in specimens which negatively correlated with the expression level of phosphorylated pRB and poorer outcome. Moreover, our results demonstrated that SPARC negatively regulated pancreatic cell growth in vitro. Furthermore, we disclosed that the activation of p53 and p27Kip1 may involve in the effect of SPARC on pancreatic cancer cells. SPARC is downregulated in pancreatic cancer cells and retards the growth of pancreatic cancer cell. Taken together, these results indicate SPARC may be a potential target for pancreatic cancer therapy.


SPARC Pancreatic ductal adenocarcinoma Cell cycle 



This work was sponsored by The Natural Science Foundation of Jiangsu Province (Youth Fund), grant number: BK20130475, Zhenjiang Science and Technology Pillar Program, grant numbers: SH2012030 and SH2012031, The Foundation for Young Scientists of affiliated Hospital of Jiangsu University (grant number: JDFYRC2013009), and post-doctoral research funding schemes of Jiangsu Province (grant number: 1302096B)

Conflicts of interest



  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Cohen SJ, Pinover WH, Watson JC, Meropol NJ. Pancreatic cancer. Curr Treat Options in Oncol. 2000;1:375–86.CrossRefGoogle Scholar
  3. 3.
    Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer. 1995;31A:882–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMedGoogle Scholar
  5. 5.
    Lane TF, Sage EH. The biology of Sparc, a protein that modulates cell-matrix interactions. FASEB J. 1994;8:163–73.PubMedGoogle Scholar
  6. 6.
    Mason IJ, Taylor A, Williams JG, Sage H, Hogan BL. Evidence from molecular cloning that Sparc, a major product of mouse embryo parietal endoderm, is related to an endothelial cell ‘culture shock’ glycoprotein of mr 43,000. EMBO J. 1986;5:1465–72.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Schwarzbauer JE, Spencer CS. The Caenorhabditis elegans homologue of the extracellular calcium binding protein Sparc/osteonectin affects nematode body morphology and mobility. Mol Biol Cell. 1993;4:941–52.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Neuzillet C, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E. Stromal expression of Sparc in pancreatic adenocarcinoma. Cancer Metastasis Rev. 2013;32:585–602.CrossRefPubMedGoogle Scholar
  9. 9.
    Franke K, Carl-McGrath S, Rohl FW, Lendeckel U, Ebert MP, Tanzer M, et al. Differential expression of Sparc in intestinal-type gastric cancer correlates with tumor progression and nodal spread. Transl Oncol. 2009;2:310–20.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Girotti MR, Fernandez M, Lopez JA, Camafeita E, Fernandez EA, Albar JP, et al. Sparc promotes cathepsin b-mediated melanoma invasiveness through a collagen i/alpha2beta1 integrin axis. J Investig Dermatol. 2011;131:2438–47.CrossRefPubMedGoogle Scholar
  11. 11.
    Liu H, Xu Y, Chen Y, Zhang H, Fan S, Feng S, et al. Rna interference against Sparc promotes the growth of u-87 mg human malignant glioma cells. Oncol Lett. 2011;2:985–90.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Atorrasagasti C, Malvicini M, Aquino JB, Alaniz L, Garcia M, Bolontrade M, et al. Overexpression of Sparc obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells. Int J Cancer. 2010;126:2726–40.PubMedGoogle Scholar
  13. 13.
    Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ, Hsieh FJ. Sparc (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J. 2010;16:305–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. Sparc promoter hypermethylation in colorectal cancers can be reversed by 5-aza-2′deoxycytidine to increase Sparc expression and improve therapy response. Br J Cancer. 2008;98:1810–9.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Puolakkainen PA, Brekken RA, Muneer S, Sage EH. Enhanced growth of pancreatic tumors in Sparc-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res. 2004;2:215–24.PubMedGoogle Scholar
  16. 16.
    Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH. Enhanced growth of tumors in Sparc null mice is associated with changes in the Ecm. J Clin Invest. 2003;111:487–95.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Guweidhi A, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, et al. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg. 2005;242:224–34.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, et al. Sparc/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, Xie D. Involvement of cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer. 2008;99:1656–67.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B, et al. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-t-cell factor/Lef signaling. J Biol Chem. 2007;282:36571–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Feng P, Wang B, Ren EC. Cyr61/ccn1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. Int J Biochem Cell Biol. 2008;40:98–109.CrossRefPubMedGoogle Scholar
  22. 22.
    Taylor WR, Stark GR. Regulation of the g2/m transition by p53. Oncogene. 2001;20:1803–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Toyoshima H, Hunter T. P27, a novel inhibitor of g1 cyclin-cdk protein kinase activity, is related to p21. Cell. 1994;78:67–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang C, Hou X, Mohapatra S, Ma Y, Cress WD, Pledger WJ, et al. Activation of p27kip1 expression by e2f1. A negative feedback mechanism. J Biol Chem. 2005;280:12339–43.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Zhengfa Mao
    • 1
  • Xiaoyan Ma
    • 2
  • Xin Fan
    • 1
  • Lei Cui
    • 1
  • Ting Zhu
    • 1
  • Jianguo Qu
    • 1
  • Jianxin Zhang
    • 1
  • Xuqing Wang
    • 1
    Email author
  1. 1.Department of General SurgeryAffiliated Hospital of Jiangsu UniversityZhenjiangPeople’s Republic of China
  2. 2.Department of Gynaecology and ObstetricsAffiliated Hospital of Jiangsu UniversityZhenjiangPeople’s Republic of China

Personalised recommendations